Vestal Point Capital LP Sells 500,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Vestal Point Capital LP decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 66.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 250,000 shares of the biotechnology company's stock after selling 500,000 shares during the period. Ascendis Pharma A/S makes up about 2.8% of Vestal Point Capital LP's holdings, making the stock its 11th largest holding. Vestal Point Capital LP owned 0.41% of Ascendis Pharma A/S worth $37,328,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ASND. DNB Asset Management AS purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter valued at $456,000. Harbor Capital Advisors Inc. raised its position in Ascendis Pharma A/S by 137.2% during the second quarter. Harbor Capital Advisors Inc. now owns 52,200 shares of the biotechnology company's stock valued at $7,119,000 after purchasing an additional 30,194 shares in the last quarter. SG Americas Securities LLC lifted its stake in Ascendis Pharma A/S by 221.0% during the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company's stock worth $833,000 after purchasing an additional 4,205 shares during the last quarter. Legato Capital Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 167.6% in the 2nd quarter. Legato Capital Management LLC now owns 4,324 shares of the biotechnology company's stock worth $590,000 after purchasing an additional 2,708 shares in the last quarter. Finally, Searle & CO. bought a new position in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $205,000.

Analyst Ratings Changes

A number of research firms recently weighed in on ASND. Oppenheimer dropped their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Jefferies Financial Group upped their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research report on Tuesday, August 13th. Finally, Wedbush reiterated an "outperform" rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and an average target price of $191.77.

Ascendis Pharma A/S Price Performance

ASND stock traded down $0.24 during trading on Friday, reaching $136.08. The company had a trading volume of 491,959 shares, compared to its average volume of 451,948. Ascendis Pharma A/S has a 52 week low of $97.86 and a 52 week high of $161.00. The business has a 50 day moving average of $132.21 and a 200 day moving average of $132.24. The company has a market cap of $8.25 billion, a P/E ratio of -16.87 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analysts' expectations of $94.74 million. Research analysts expect that Ascendis Pharma A/S will post -7.45 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.